Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation

Background Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. Objectives The objectives were to evaluate the clinical effectiveness, safety and cost-effectiveness of non-bisphosphonates {denosumab [Prolia ® ; Amgen Inc., Thousand Oaks, CA, USA], raloxifene [Evista ® ; Daiichi Sankyo Company, Ltd, Tokyo, Japan], romosozumab [Evenity ® ; Union Chimique Belge (UCB) S.A. (Brussels,...